[Use of dabigatran etexilate for treatment of deep vein thrombosis and pulmonary artery thromboembolism].
The authors present herein their experience in oral administration of dabigatran etexilate for treatment of lower-limb deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia, as well as assessment of its efficacy and safety. The study included a total of nineteen 20-to-79-year-old patients (11 men and 8 women) with venous thromboembolic complications. An inclusion criterion was the presence of lower-limb deep vein thrombosis documented in the B-mode in ultrasonography alone or in a combination with pulmonary thromboembolism confirmed by angiopulmonography end echocardiography. The exclusion criteria were as follow: oncological diseases, a history of surgical interventions, acute infections, skeletal injuries and fractures, long-term immobilization, age under 20 and over 79 years. For 6 months the authors evaluated patients' tolerance of dabigatran, its efficacy, as well as the profile of safety concerning the development of major and clinically significant haemorrhage. It was determined that administration of dabigatran in patients with confirmed thrombophilia at a fixed dose (150 mg twice daily) during 6 months for treatment of lower-limb venous thromboses and pulmonary thromboembolism turned out to be effective and safe, with the drug possessing a good profile of safety and its administration requiring no routine laboratory monitoring.